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Abstract 
Immune thrombocytopenia (ITP) in adults
is an acquired chronic immune-mediated dis-
order defined by isolated thrombocytopenia. In
recent  years,  an  improved  understanding  of
the pathophysiology of ITP has been achieved
and it is now accepted that the disorder is due
to  increased  platelet  destruction  and
decreased platelet production from megakary-
ocytes.  Thrombopoietin  (TPO)-receptor  ago-
nists (romiplostim and eltrombopag) are new
therapeutic modalities in the treatment of ITP.
Here we describe a case of an elderly patient
with  severe  ITP  who  presented  complete
remission after short-term use of romiplostim
(only 3 weekly doses). This finding is quite
interesting as the TPO-receptor agonists are,
so far, believed to rarely lead to off-treatment
sustained remission. The common notion of
long-term  use  of  romiplostim  could  be  re-
examined in future studies. Furthermore, the
short  term  treatment  with  romiplostim  may
reduce the cost and the risk of side effects.
Introduction
Immune  thrombocytopenia  (ITP)  is  an
autoimmune  syndrome  involving  antibody-
and cell-mediated destruction of platelets and
suppression  of  platelet  production  that  may
predispose to bleeding. Estimates of the inci-
dence of adult-onset ITP range from approxi-
mately 1.6 to 3.9 per 100,000 persons per year,
with a prevalence ranging from 9.5 to 23.6 per
100,000 persons, based on diagnostic codes in
the UK health registry. ITP is generally a diag-
nosis of exclusion and in adults typically shows
an  insidious  onset  and  follows  a  chronic
course.1,2 In this case report, the first in the lit-
erature to our knowledge, we describe an 83-
year-old man who responded after short-term
therapy with the TPO-receptor agonist romi-
plostim with complete remission, whereas pre-
vious first-line interventions had not achieved
response. 
Case Report
An 83-year-old Caucasian male was admit-
ted to our clinic because of sudden onset of
gastrointestinal bleeding. His medical history
included diagnosis of Rendu-Osler-Weber dis-
ease  and  a  hospitalization  for  ITP  2  years
before previous admission, successfully treat-
ed with corticosteroids. On physical examina-
tion the patient had no bruises or petechiae,
was  afebrile,  his  pulse  was  regular  and  his
blood pressure and respiratory rate were nor-
mal. Clear lung sounds were found bilaterally.
No  focal  neurologic  deficits  were  found.  In
general,  the  patient  was  appropriately  alert
and oriented.
Laboratory  studies  were  ordered  and
revealed thrombocytopenia and anemia (PLT: 8
ﾥ109/L,  Hb  10.5  g/dL).  The  peripheral  blood
smear showed thrombocytopenia without any
morphological  abnormalities.  Additionally,
immunologic and virology tests were carried
out revealing no abnormality. 
The patient was first treated with coricos-
teroids  (prednisolone  1  mg/kg)  but  without
any response. A bone marrow aspiration and
biopsy were performed with results compatible
with ITP.
The patient’s bleeding symptoms worsened
and now also included hematuria and vesicular
bleeding.  Combined  prednisolone  and  intra-
venous immunoglobulin (IVIg 400 mg/kg for 4
days)  was  then  administered,  with  no
response. Platelet transfusion was given, in an
attempt to raise the platelet count quickly, as
indicated in cases of emergency bleeding. The
platelet  count  still  did  not  increase  at  all.
Rituximab, a monoclonal antibody against B-
cell antigen CD-20, (375 mg/m2) was given in
combination to corticosteroids, but still with-
out success. Splenectomy was not an option
due to the patient’s refusal to undergo the spe-
cific  procedure.  Romiplostim  (1  ʼg/kg  of  a
weekly  subcutaneous  injection)  in  combina-
tion with prednisolone (50 mg/day) was decid-
ed.  On  the  3rd weekly  dose  (3  mg/kg)  the
platelet count increased up to 100ﾥ109 /L. The
4th dose was postponed since the platelet count
was 700ﾥ109/L (Figure 1). Acetylsalicylic acid
was added as a thromboprophylactic measure
and the patient was then discharged. After 3
months of follow up (under corticosteroid ther-
apy in the tapering phase, ie: 4 mg of methyl-
prednisolone day after day) the platelet count
was still normal, at a level of approximately
400ﾥ109/L. The patient remained in complete
remission during the one year follow up.
Discussion
Immune  thrombocytopenia  (ITP)  is  an
acquired autoimmune disorder characterized
by  isolated  thrombocytopenia,  defined  as  a
peripheral  blood  platelet  count  less  than
100ﾥ109/L, and the absence of any obvious ini-
tiating and/or underlying cause of thrombocy-
topenia.  ITP  is  classified  by  duration  into:
newly diagnosed (diagnosis to 3 months), per-
sistent (3-12  months’  duration)  and  chronic
(>12 months’ duration). Severe ITP is defined
as  bleeding  at  presentation  or  during  treat-
ment requiring additional therapy. Refractory
ITP is defined as the presence of severe ITP
after  splenectomy.  Non-splenectomized
patients  are  defined  as  responders  or  non-
responders to various treatments.3
Signs  and  symptoms  can  vary  widely.  In
some cases ITP is asymptomatic, whereas in
others  development  of  visible  signs  such  as
bruises, petechiae, epistaxis or serious bleed-
ing  episodes  occur  (gastrointestinal  hemor-
rhage, skin or mucosal hemorrhage, intracra-
nial hemorrhage). The severity of thrombocy-
topenia seems to correlate to some extent with
the bleeding risk.4
The pathogenesis of ITP is based on a com-
bination of enhanced platelet clearance and a
variably  impaired  platelet  production.5,6 The
disorder  is  due  to  a  diversity  of  immune
effects, so no single therapeutic approach is
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effective for all patients with ITP. Variations in
the etiology of the disorder explain why some
patients respond to therapy that suppresses B-
cells, others to drugs that suppress T-cells and
others  to  agents  that  activate  throm-
bopoiesis.7-9 The TPO-receptor agonists (romi-
plostim and eltrombopag) are new therapeutic
modalities that have recently been licenced for
the  treatment  of  ITP.10-13 Reported  adverse
effects  of  these  agents  have  been  relatively
mild,  although  rare  serious  events  such  as
bone marrow reticulin formation, thromboem-
bolic episodes and liver function test abnor-
malities  have  occurred.  Romiplostim  and
eltrombopag  bear  no  structural  homology  to
TPO but can both bind and activate the TPO
receptor. Up to now, TPO-receptor agonists are
used  for  patients  at  risk  of  bleeding,  who
relapse after splenectomy or who have a con-
traindication  to  splenectomy  and  who  have
already failed at least one other therapy.14They
are a costly option, but in view of the good tol-
erability and low toxicity they are often chosen
for treatment.
In  our  case  the  patient  was  treated  with
romiplostim, achieved complete response after
short term administration of the drug (only 3
weekly doses) and overall tolerated treatment
very well. Since then he remains free of symp-
toms, with a stable and normal platelet count.
This finding is quite interesting as the TPO-
receptor agonists are, so far, believed to lead to
off-treatment sustained remission very rarely.
The common notion of long-term use of romi-
plostim could be re-examined in future studies
It  is  worth  mentioning  that  the  successful
response to romiplostim in our case may be
explained by pre-stimulated thrombopoiesis as
a result of the previous corticosteroid, IVIg and
rituximab treatment. The pre-treatment with
rituximab may be actually responsible for the
excellent response to romiplostim. In recent
bibliographic  data,  two  cases  have  been
described  with  effective  treatment  of  severe
ITP by combined rituximab and romiplostim.15
Our case accords with these findings with the
difference that the patient received only one
dose of rituximab and 3 doses of romiplostim
afterwards.
Despite the plethora of therapeutic strate-
gies of ITP there is no evidence to guide an
algorithm of treatment for recurrent or persist-
ent cases of ITP. According to the 2011 evi-
dence  based  practice  guidelines  of  the
American Society of Hematology for ITP, addi-
tional studies are needed concerning the first-
line therapy for the management of bleeding
and the second-line therapies.14 If treatment is
required it should be individualized for each
patient and the final judgment should be made
after thorough investigation of individual cir-
cumstances. The main goal is to achieve an
increase of the platelet count that is hemosta-
tic rather than normal.
The role of TPO agonists in the manage-
ment  of  ITP  will  evolve  in  the  future  when
results from clinical trials and experience will
finally clarify their efficacy and potential side
effects. For this purpose collaboration between
health care centers is imperative. In this way
the treatment of ITP will transform from opin-
ion based to evidence-based. Nowadays, romi-
plostim seems a very promising therapy for the
treatment of refractory forms of ITP so more
clinical trials are needed in order to clarify the
duration, dosage, effectiveness and safety of
the drug either as monotherapy or combina-
tion therapy with other agents.
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Figure 1. Platelets
response  after
treatment  with
romiplostim.